It was recently reported that the S1R agonist fluvoxamine prevents clinical deterioration of symptomatic COVID-19 and the persistence of residual symptoms (Lenze et al., 2020; Seftel & Boulware, 2021). The gene discussed is TMBIM4; the disease is COVID-19.